CLCharles Lu

Charles Lu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Charles Lu has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Spatial proteomics for investigating solid tumor resistance mechanisms

    by Xin Ming M. Zhou, Anjali J. D’aMiano, Charles Lu, Vrinda Madan, Sara Khoshniyati, Jack Kollings, Noah E. Sunshine, Sachin S. Surwase, Joel C. Sunshine

    Spatial proteomics technologies have been pivotal in profiling tumor immune microenvironments at single-cell resolution, advancing our understanding of cancer biology, identifying key cell populations in solid tumors, and predicting treatment responses. Although immune checkpoint and molecular inhibitors have revolutionized cancer care, resistance mechanisms remain a major therapeutic challenge that hinder productive responses in a notable fraction of cancer patients. In this review, we outline current spatial proteomics and computational analysis tools for studying the tumor immune microenvironment and discuss how spatial proteomics techniques have helped elucidate cancer resistance mechanisms across multiple tumor types. In this process, we highlight the importance of investigating immunosuppressive cell populations that can mediate cancer resistance, specifically with regard to their localization, protein signatures, and surrounding interactions. Finally, we provide a look ahead at future applications of artificial intelligence/machine learning and multi-omics approaches that will help further propel our understanding of cancer resistance mechanisms through spatial biology research.


  • Open Access

    Effect of systemic glucocorticoid immunosuppression timing, dose, and duration on overall survival among immune checkpoint inhibitor recipients: a retrospective multicohort study

    by Guihong Wan, Nga Nguyen, Charles Lu, Sara Khattab, Boshen Yan, Munachimso Amadife, Bonnie W. Leung, Wenxin Chen, Ahmad Rajeh, Kimberly Tang, et al.

    Background Systemic immunosuppression (sISP), particularly with glucocorticoids, is commonly used among patients receiving immune checkpoint inhibitor (ICI) therapy. Although recent studies have demonstrated that sISP is associated with poor outcomes in ICI recipients, there is limited information on how the timing, dose, and duration of sISP affect overall survival (OS). This multi-cohort retrospective study aims to address these gaps. Methods This study included 13,086 ICI recipients from Massachusetts General Hospital, Brigham and Women’s Hospital, and Dana-Farber Cancer Institute (MGBD) between May 31, 2015, and October 11, 2021. For independent validation, 26,172 ICI recipients were identified from the TriNetX database between April 30, 2010, and October 11, 2021, using 2:1 propensity score matching. Multivariable survival analyses were conducted with Accelerated Failure Time (AFT) models, reporting Time Ratios (TRs) and 95% Confidence Intervals (CIs), where TRFindings In the MGBD cohort, sISP within one year of ICI initiation was associated with worse OS compared to patients without sISP via landmark analysis. This association was accentuated among patients receiving sISP closer to ICI initiation, with those receiving sISP within one month of ICI initiation having the worst outcomes (TR: 0.49; 95% CI: 0.44-0.54; pInterpretation Three key factors are associated with significantly worse OS: sISP near ICI initiation, higher sISP dose, and longer sISP duration, regardless of indication. These findings provide clinicians with valuable information to guide sISP management among ICI recipients. Funding NIH, USA Evidence before this study We reviewed PubMed and existing literature for studies on systemic immunosuppression (sISP), particularly glucocorticoids, and outcomes among immune checkpoint inhibitor (ICI) recipients. Previous research, including clinical trial studies, indicated that sISP, especially at higher doses or for managing immune-related adverse events (irAEs), was associated with poorer survival. However, studies were limited by small sample sizes, focused on single cancer types, or did not comprehensively assess the nuanced impacts of sISP timing relative to ICI initiation, dose, and duration across diverse cancer types and ICI indications. Thus, a clear understanding of these specific parameters in large, real-world cohorts was lacking. Added value of this study This multi-cohort study analyzed approximately 40,000 ICI recipients, leveraging data from a large academic medical center system (MGBD) and validating findings in a national, population-level database (TriNetX) with access to granular patient-level data. We comprehensively investigated how the timing, dose, and duration of systemic glucocorticoid immunosuppression influence overall survival across a pan-cancer population. Our large scale and detailed approach provide robust, generalizable insights into these critical factors, addressing limitations of prior, smaller, or more narrowly focused investigations. Implications of all the available evidence Our findings offer clinicians critical, actionable insights for managing systemic glucocorticoid immunosuppression in patients receiving ICI therapy. Knowing that sISP administered near ICI initiation, at higher doses, or for longer durations is associated with significantly worse overall survival can guide clinical decision-making. This allows for more informed risk-benefit discussions, strategies to minimize steroid exposure when feasible (e.g., lowest effective dose, shortest duration), and consideration of steroid-sparing alternatives, ultimately aiming to optimize survival outcomes for cancer patients on ICI therapy.


  • Open Access

    gen3DNet: An R Package for Generating 3D Network Models

    by Paul Morrison, Tina Tang, Charles Lu, Shamim Mollah

    Motivation: Networks are ubiquitous to organize and represent data in the real world such as the biomedical networks, social networks, etc. Due to the attractive property of networks which can explicitly capture the rich relationships among data samples, there is an increasing demand to transform linkage-free data to graph-structure data for efficient downstream analyses. Existing works typically focus on representing a single data object like gene expression profile in a homogeneous 2D network, which fail to deal with situations where two different data objects are involved to create a 3D heterogeneous network. Results: In this paper, we introduce an R package, gen3DNet (a generic version of the iPhDNet), for generating 3D network models from two correlated objects with shared common factors. Specifically, gen3DNet builds the relationships between samples and shared factors using the non-negative matrix factorization, where three clustering techniques are evaluated to determine the number of functional modules. In addition, it builds the relationships between samples from the two distinct data objects based on a partial least squares regression model. Usage of the package is illustrated through a real-world application. GitHub URL Source code is available at https://github.com/mollahlab/gen3DNet


  • Open Access

    Genome-scale functional genomics screening highlights genes impacting protein fucosylation in Chinese hamster ovary cells

    by Kari Barlan, Gaurang P Bhide, Derek R White, Marc R Lake, Charles Lu, Stephanie E Rieder, Lianchun Fan, Chen-Lin Hsieh


  • Open Access

    HOCMO: A Tensor-based Higher-Order Correlation Model to Deconvolute Epigenetic Microenvironment in Breast Cancer

    by Charles Lu, Rintsen Sherpa, Liubou Klindziuk, Stefanie Kriel, Shamim Mollah, Min Shi

    Motivation An in-depth understanding of epithelial breast cell responses to the growth-promoting ligands is required to elucidate how the microenvironment (ME) signals affect cell-intrinsic regulatory networks and the cellular phenotypes they control, such as cell growth, progression, and differentiation. This is particularly important in understanding the mechanisms of breast cancer initiation and progression. However, the current mechanisms by which the ME signals influence these cellular phenotypes are not well established. Results We developed a high-order correlation method using proteomics data to reveal the regulatory dynamics among proteins, histones, and six growth-promoting ligands in the MCF10 cell line. In the proposed method, the protein-ligand and histone-ligand correlations at multiple time points are first encoded in two three-way tensors. Then, a non-negative tensor factorization model is used to capture and quantify the protein-ligand and histone-ligand correlations spanning all time points, followed by a partial least squares regression process to model the correlations between histones and proteins. Our method revealed the onset of specific protein-histone signatures in response to growth ligands contributing to distinct cellular phenotypes that are indicative of breast cancer initiation and progression. Contact smollah{at}wustl.edu